{"id":"NCT02706847","sponsor":"AbbVie","briefTitle":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs","officialTitle":"A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-15","primaryCompletion":"2017-04-03","completion":"2022-02-08","firstPosted":"2016-03-11","resultsPosted":"2019-10-07","lastUpdate":"2023-02-08"},"enrollment":499,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Upadacitinib","otherNames":["ABT-494","RINVOQ®"]}],"arms":[{"label":"Upadacitinib 15 mg","type":"EXPERIMENTAL"},{"label":"Upadacitinib 30 mg","type":"EXPERIMENTAL"},{"label":"Placebo / Upadacitnib 15 mg","type":"PLACEBO_COMPARATOR"},{"label":"Placebo / Upadacitnib 30 mg","type":"PLACEBO_COMPARATOR"}],"summary":"The study objective of Period 1 (Day 1 to Week 24) is to compare the safety and efficacy of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of participants with moderately to severely active rheumatoid arthritis (RA) who are on a stable dose of csDMARDs and had an inadequate response to or intolerance to at least 1 bDMARD.\n\nThe study objective of Period 2 (Week 24 to Week 260) is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants with RA who completed Period 1.","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":28.4,"sd":null},{"arm":"Upadacitinib 15 mg","deltaMin":64.6,"sd":null},{"arm":"Upadacitinib 30 mg","deltaMin":56.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":2},"locations":{"siteCount":188,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Estonia","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Latvia","New Zealand","Poland","Portugal","Puerto Rico","Russia","Slovakia","South Korea","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["29908670","40875187","39053948","37982966","37945286","37308218","36794283","36754548","36715850","36125701","34041702","33115760","31791386","31610021"],"seeAlso":["https://www.rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":169},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Rheumatoid arthritis","Nasopharyngitis","Bronchitis"]}}